379 related articles for article (PubMed ID: 28185916)
1. DNA vaccines for prostate cancer.
Zahm CD; Colluru VT; McNeel DG
Pharmacol Ther; 2017 Jun; 174():27-42. PubMed ID: 28185916
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines for the treatment of prostate cancer.
Alam S; McNeel DG
Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
Johnson LE; Olson BM; McNeel DG
J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
8. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.
Colluru VT; McNeel DG
Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128
[TBL] [Abstract][Full Text] [Related]
9. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
10. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines for cancer.
Boyd D; Hung CF; Wu TC
IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical development of DNA vaccines for prostate cancer.
Colluru VT; Johnson LE; Olson BM; McNeel DG
Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
16. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
20. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]